A Phase 1, First-in-human Study of VX-634

Completed · Phase 1 · Has a placebo group

Conditions studied: Alpha 1-Antitrypsin Deficiency

In brief

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-634 at various doses.

Key facts

Study ID

NCT05579431

Run by

Vertex Pharmaceuticals Incorporated

People needed

127

Starts

2022-10-13

Expected to finish

2023-11-13

Last updated by the study team

2024-03-12

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

• Celerion - Tempe — Tempe, Arizona, United States
• University of Florida — Gainesville, Florida, United States
• Central Florida Pulmonary Group, P.A. — Orlando, Florida, United States
• ICON Lenexa — Lenexa, Kansas, United States
• ICON Salt Lake City — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.